Preoperative Pembrolizumab Plus Chemoradiotherapy (PPCT) for Locally Advanced Resectable ESCC: PALACE‑2 Phase 1/2 Results and Immune‑Microenvironment Insights
Posted innews Oncology

Preoperative Pembrolizumab Plus Chemoradiotherapy (PPCT) for Locally Advanced Resectable ESCC: PALACE‑2 Phase 1/2 Results and Immune‑Microenvironment Insights

PALACE‑2 reports that preoperative pembrolizumab combined with chemoradiotherapy produced a 43.2% pathologic complete response in resectable, locally advanced esophageal squamous cell carcinoma, with acceptable short‑term survival and a high rate of grade ≥3 toxicities; IL‑6 emerged as a potential predictive and targetable mediator of response.
Tumor Microenvironment-Responsive Mn-Based Nanoplatform Activates cGAS-STING Pathway Coupled with Metabolic Interference for Enhanced Antitumor Therapy
Posted inAllergy & Immunology Clinical Updates news Oncology Specialties

Tumor Microenvironment-Responsive Mn-Based Nanoplatform Activates cGAS-STING Pathway Coupled with Metabolic Interference for Enhanced Antitumor Therapy

A novel Mn-based nanoplatform, LT@MnO@MON-HA (LMMH), responsive to tumor microenvironment triggers metabolic disruption and robust cGAS-STING activation, potentiating chemodynamic therapy and immunotherapy for improved tumor suppression.